Gilad Rosenberg

Gilad Rosenberg is a physician and neuroscience drug-development executive. Allucent lists him as Executive Medical Director and Therapeutic Area Medical Lead for Neuroscience, with 25+ years of experience managing pre-clinical, clinical, and regulatory aspects of drug development across all phases. Allucent says his development experience spans neurological indications as well as oncology and hematology.

Before Allucent, Rosenberg was Medical Director at Clal Biotechnology Industries, an Israeli life-sciences investment company listed on the Tel Aviv Stock Exchange. Edison Investment Research reported that he joined CBI’s team in 2016, bringing clinical-development and scientific-assessment experience; CBI’s current site no longer lists him on the management team, so this appears to be a former CBI role.

Earlier in his career, Rosenberg was Vice President of Clinical Development at D-Pharm and Medical Director for Merck Sharp & Dohme’s Israeli subsidiary. A 2011 International Journal of Stroke paper on the MACSI Phase III acute ischemic stroke trial listed him at D-Pharm and disclosed that he was an employee and held stock options in D-Pharm, the trial sponsor.

Rosenberg graduated cum laude from the Rappaport Faculty of Medicine at the Technion - Israel Institute of Technology, completed postgraduate training in neurology at Hadassah Medical Center in Jerusalem, and earned an MSc in neuroscience with distinction from the University of Oxford. His LinkedIn profile also lists University of Oxford education from 2004 to 2005 and membership in the American Academy of Neurology issued in January 2007.

• No primary source found confirming that Rosenberg is currently an active angel investor or publishing a personal investment thesis. The most supportable investment context is his former CBI role and his current Allucent clinical-development work.
• CBI states that it identifies and nurtures ventures developing proprietary solutions for unmet medical needs with substantial market potential.
• CBI’s portfolio spans seed to maturity and includes private and publicly traded companies; sector coverage includes biotechnology, pharmaceuticals, diagnostics, and medical devices.
• Rosenberg’s own Allucent writing emphasizes rigorous clinical-trial design in neuroscience: validated biomarkers, rater training, site selection, patient retention, placebo-response mitigation, and practical recruitment plans for rare neuropsychiatric disorders.
• His likely diligence strength is clinical and translational assessment in neuroscience drug development, especially whether a program has credible biology, endpoints, biomarkers, regulatory strategy, and operational feasibility.